The pioglitazone group showed reduced liver triglyceride content and improved histological scores of steatosis, inflammation, ballooning and fibrosis.14 Aithal et al compared the standard diet and exercise with pioglitazone or with placebo in 74 nondiabetic patients with NASH.12 The pioglitazone group showed reduced alanine aminotransferase levels and improved histologic features of hepatic injury, Mallory bodies and fibrosis compared with the placebo group. The gene discussed is GPT; the disease is steatosis.